Richard Epstein, Apr 19, 2007
This paper gives a brief analysis of the role of contingent commissions in insurance markets. These contracts have received a great deal of attention in recent years because they were the focal point of major criminal enforcement actions that New York´s then-Attorney General, now Governor, Eliot Spitzer, brought against prominent insurance brokers, including the largest three brokers: Marsh & McLennan, Aon, and Willis. Those prosecutions resulted in fines and other sanctions being lodged against these brokerage houses, as well as continuing criminal prosecution against employees who were engaged in some bid-rigging schemes. On balance, a strong case can be made out for requiring disclosure of contingent commissions and for banning any form of bid-rigging. The adverse consequences of nondisclosures are more difficult to track than those for collusion, given the difficulty of showing in individual cases a connection between the nondisclosure and any pecuniary loss sustained by the insured. The case for banning all contingent commissions in the absence of concealment or bid-rigging, still remains not proven. It is not easy to come up with a powerful efficiency explanation for the use of contingent commission agreements, but if these agreements continue to be adopted with full disclosure in the absence of collusion, then it seems premature to ban them just because our incomplete knowledge of how brokerage markets work does not supply a compelling efficiency justification for their use.
Featured News
Toast Faces FTC Lawsuit Over Alleged Hidden Fees and Subscription Practices
Oct 29, 2026 by
CPI
Amazon, Uber and Instacart Challenge NYC Delivery Worker Protections in Federal Court
Oct 29, 2026 by
CPI
Wall Street Law Giant Weil Gotshal to Dissolve After Partner Exodus
Oct 29, 2026 by
CPI
DoorDash to Acquire Instacart in $17 Billion Grocery Delivery Deal
Oct 29, 2026 by
CPI
Anthropic Urges California to Give Courts Power to Block High-Risk AI Models
Oct 29, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI